ଆଗୋମେଲାଟିନ

ଆଗୋମେଲାଟିନ
Clinical data
Trade names	Melitor, Thymanax, Valdoxan, others
AHFS/Drugs.com	International Drug Names
data	EU EMA: yes;
Pregnancy; category	AU: B1 ;
Routes of; administration	By mouth
ATC code	N06AX22 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only) ; UK: POM (Prescription only) ;
Pharmacokinetic data
Bioavailability	1%
Protein binding	95%
Metabolism	hepatic (90% CYP1A2 and 10% CYP2C9)
Elimination half-life	1–2 hours
Excretion	Renal (80%, mostly as metabolites)
Identifiers
	IUPAC name N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide;
CAS Number	138112-76-2 ;
PubChem CID	82148;
IUPHAR/BPS	198;
DrugBank	DB06594 ;
ChemSpider	74141 ;
UNII	137R1N49AD;
KEGG	D02578 ;
ChEMBL	CHEMBL10878 ;
ECHA InfoCard	100.157.896
Chemical and physical data
Formula	C15H17NO2
Molar mass	243.301 g/mol
3D model (JSmol)	Interactive image;
	SMILES O=C(NCCc1c2c(ccc1)ccc(OC)c2)C;
	InChI InChI=1S/C15H17NO2/c1-11(17)16-9-8-13-5-3-4-12-6-7-14(18-2)10-15(12)13/h3-7,10H,8-9H2,1-2H3,(H,16,17) ; Key:YJYPHIXNFHFHND-UHFFFAOYSA-N ;
(what is this?) (verify)

ଇଂରାଜୀ ଲିଙ୍କ

https://or.wikipedia.org/wiki/Agomelatine

ଆଗୋମେଲାଟିନ (ଇଂରାଜୀ ଭାଷାରେ Agomelatine ) ଏକ ଅସ୍ୱାଭାବିକ ଅବସାଦରୋଧୀ (atypical antidepressant) ଔଷଧ ଯାହା ପ୍ରମୁଖ ଅବସାଦ ବେମାରୀର ଚିକିତ୍ସା ନିମନ୍ତେ ଦିଆଯାଏ ।^[୨] ଏକ ଅନୁଶୀଳନରୁ ଜଣାଯାଏ, ଏହା ଅନ୍ୟାନ୍ୟ ଅବସାଦରୋଧୀ ଔଷଧ ଅପେକ୍ଷା ଗୁଣାତ୍ମକ ଭାବରେ କିଛି ଅଧିକ ନୁହେଁ ।^[୨]^[୩] ସେହିଭଳି ଅନ୍ୟ ଏକ ଅନୁଶୀଳନରେ ଦେଖାଗଲା ଏହା ଅନ୍ୟାନ୍ୟ ଅବସାଦରୋଧୀ ଔଷଧ ସ‌ହିତ ତୁଳନାତ୍ମକ ଭାବରେ ସମାନ ।^[୪]

ଏହାର ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଓଜନ ବୃଦ୍ଧି, ଥକ୍କା ଅନୁଭବ, ଯକୃତ ସମସ୍ୟା, ଅଇ, ମୁଣ୍ଡ ବିନ୍ଧା ଓ ଉଦ୍‌ବେଗ ହୋଇପାରେ ।^[୫]^[୬] ଯକୃତ ସମସ୍ୟା ସମ୍ଭାବନା ଥିବା ଯୋଗୁ ବାରମ୍ବାର ରକ୍ତ ପରୀକ୍ଷା କରିବାକୁ ହୁଏ ।^[୭] ଡିମେନ୍ସିଆ ରୋଗରେ ଓ ୭୫ ବର୍ଷ ବୟସ ପରେ ଏହା ଦେବାକୁ ସୁପାରିସ କରାଯାଏ ନାହିଁ ।^[୫] ଅନ୍ୟାନ୍ୟ ଅବସାଦରୋଧୀ ଔଷଧ ଅପେକ୍ଷା ଏହାର କମ୍ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟା ଥିବା ଏକ ଅନୁଶୀଳନରୁ ଜଣାଯାଏ ।^[୨] ଏହା ଏକ ମେଲାଟୋନିନ ଆଗୋନିସ୍ଟ (stimulating melatonin receptors ) ଓ ସିଲେକ୍ଟିଭ ସେରୋଟୋନିନ ଆଣ୍ଟାଗୋନିସ୍ଟ (blocking serotonin receptors) ଭାବରେ କାମ କରେ ।^[୭]

ସନ ୨୦୦୯ରେ ୟୁରୋପରେ ଓ ସନ ୨୦୧୦ରେ ଅଷ୍ଟ୍ରେଲିଆରେ ଆଗୋମେଲାଟିନ ଡାକ୍ତରୀ ବ୍ୟବ‌ହାର ନିମନ୍ତେ ସ୍ୱୀକୃତ ହୋଇଥିଲା ।^[୭] ଯୁକ୍ତରାଷ୍ଟ୍ର ଆମେରିକାରେ ଏହା ସ୍ୱୀକୃଟ କରିବା ପ୍ରଚେଷ୍ଟ ସନ ୨୦୧୧ରେ ଶେଷ ହୋଇଗଲା ।^[୭] ସର୍ଭିଅର (Servier) ନାମକ କମ୍ପାନୀ ଏହାକୁ ପ୍ରସ୍ତୁତ କରିଥିଲେ ।^[୭] ସନ ୨୦୧୯ରେରେ ସଂଯୁକ୍ତ ରାଷ୍ଟ୍ରରେ (United Kingdom) ଏନଏଚଏସକୁ (NHS) ଏହାର ଏକ ମାସର ଡୋଜ ପିଛା ପ୍ରାୟ ୩୦ ପାଉଣ୍ଡ ଖର୍ଚ୍ଚ କରିବାକୁ ପଡ଼ୁଥିଲା ।^[୫]

ଏହା ମଧ୍ୟ ଦେଖନ୍ତୁ

ଆଧାର

1 2 3 4 5 "VALDOXAN® Product Information" (PDF). TGA eBusiness Services. Servier Laboratories Pty Ltd. 2013-09-23. Archived from the original on 2017-03-24. Retrieved 2013-10-14.
1 2 3 Guaiana G, Gupta S, Chiodo D, Davies SJ, Haederle K, Koesters M (December 2013). "Agomelatine versus other antidepressive agents for major depression". The Cochrane Database of Systematic Reviews (12): CD008851. doi:10.1002/14651858.CD008851.pub2. PMID 24343836.
↑ Taylor D, Sparshatt A, Varma S, Olofinjana O (March 2014). "Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies". BMJ. 348: g1888. doi:10.1136/bmj.g1888. PMC 3959623. PMID 24647162.
↑ Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. (April 2018). "Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis". Lancet (in English). 391 (10128): 1357–1366. doi:10.1016/S0140-6736(17)32802-7. PMC 5889788. PMID 29477251.{{cite journal}}: CS1 maint: unrecognized language (link)
1 2 3 British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 357–358. ISBN 9780857113382.
↑ "Product Information: Valdoxan, INN-agomelatine" (PDF). www.ema.europa.eu. European Medicines Agency. 13 November 2013. Archived (PDF) from the original on 29 October 2014. Retrieved 27 February 2016.
1 2 3 4 5 Norman, TR; Olver, JS (13 February 2019). "Agomelatine for depression: expanding the horizons?". Expert Opinion on Pharmacotherapy: 1–10. doi:10.1080/14656566.2019.1574747. PMID 30759026.

ବାହ୍ୟ ଲିଙ୍କ

Genf interaction table- http://www.hug-ge.ch/sites/interhug/files/structures/pharmacologie_et_toxicologie_cliniques/carte_cytochromes_2016_final.pdf February 2017

[PI-1] 1 2 3 4 5 "VALDOXAN® Product Information" (PDF). TGA eBusiness Services. Servier Laboratories Pty Ltd. 2013-09-23. Archived from the original on 2017-03-24. Retrieved 2013-10-14.

[Gua2013-2] 1 2 3 Guaiana G, Gupta S, Chiodo D, Davies SJ, Haederle K, Koesters M (December 2013). "Agomelatine versus other antidepressive agents for major depression". The Cochrane Database of Systematic Reviews (12): CD008851. doi:10.1002/14651858.CD008851.pub2. PMID 24343836.

[BMJ2014-3] Taylor D, Sparshatt A, Varma S, Olofinjana O (March 2014). "Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies". BMJ. 348: g1888. doi:10.1136/bmj.g1888. PMC 3959623. PMID 24647162.

[Cip2018-4] Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. (April 2018). "Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis". Lancet (in English). 391 (10128): 1357–1366. doi:10.1016/S0140-6736(17)32802-7. PMC 5889788. PMID 29477251.{{cite journal}}: CS1 maint: unrecognized language (link)

[BNF76-5] 1 2 3 British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 357–358. ISBN 9780857113382.

[6] "Product Information: Valdoxan, INN-agomelatine" (PDF). www.ema.europa.eu. European Medicines Agency. 13 November 2013. Archived (PDF) from the original on 29 October 2014. Retrieved 27 February 2016.

[Nor2019-7] 1 2 3 4 5 Norman, TR; Olver, JS (13 February 2019). "Agomelatine for depression: expanding the horizons?". Expert Opinion on Pharmacotherapy: 1–10. doi:10.1080/14656566.2019.1574747. PMID 30759026.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]